ArticleThe American journal of pathology2013
Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer.
Article in The American journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Olfactomedin 4 in cancer development and progression.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Apolipoprotein E ε4-Specific Relationship Between Serum Olfactomedin 4 and Alzheimer's Disease.Molecular neurobiology · 2025Article
- Interactions between microbiota and uterine corpus endometrial cancer: A bioinformatic investigation of potential immunotherapy.PloS one · 2024Article
- Characterization of olfactomedin 4+ cells in prostate and urethral-tube epithelium during murine postnatal development and in adult mice.Scientific reports · 2023Article
- Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer.Cancer gene therapy · 2023Article
- Olfactomedin 4 mediation of prostate stem/progenitor-like cell proliferation and differentiation via MYC.Scientific reports · 2020Article
- Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.International journal of cancer · 2020Article
- High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.PloS one · 2020Article
- OLFM4 Inhibits Epithelial-Mesenchymal Transition and Metastatic Potential of Cervical Cancer Cells.Oncology research · 2019Article
- OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma.Hepatology communications · 2019Article
- Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma.PloS one · 2019Article
- GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism.Cytokine & growth factor reviews · 2017Review
- Identification of differentially-expressed of Olfactomedin-related proteins 4 and COL11A1 in Iranian patients with intestinal gastric cancer.Gastroenterology and hepatology from bed to bench · 2017Article
- Retinoid Chemoprevention: Who Can Benefit?Current pharmacology reports · 2015Article
- Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway.Scientific reports · 2015Article
- Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.EBioMedicine · 2015Article
- Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer.Virchows Archiv : an international journal of pathology · 2015Article
- Robust cre-mediated recombination in small intestinal stem cells utilizing the olfm4 locus.Stem cell reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
The olfactomedin 4 (OLFM4) gene is located on chromosome 13q14.3, which frequently is deleted in human prostate cancer. However, direct genetic evidence of OLFM4 gene alteration in human prostate cancer has not yet been obtained. In this study, we investigated the genetics, protein expression, and functions of the OLFM4 gene in human prostate cancer. We found overall 25% deletions within the OLFM4 gene in cancerous epithelial cells compared with adjacent normal epithelial cells that were microdissected from 31 prostate cancer specimens using laser-capture microdissection and genomic DNA sequencing. We found 28% to 45% hemizygous and 15% to 57% homozygous deletions of the OLFM4 gene via fluorescence in situ hybridization analysis from 44 different prostate cancer patient samples. Moreover, homozygous deletion of the OLFM4 gene significantly correlated with advanced prostate cancer. By using immunohistochemical analysis of 162 prostate cancer tissue array samples representing a range of Gleason scores, we found that OLFM4 protein expression correlated inversely with advanced prostate cancer, consistent with the genetic results. We also showed that a truncated mutant of OLFM4 that lacks the olfactomedin domain eliminated suppression of PC-3 prostate cancer cell growth. Together, our findings indicate that OLFM4 is a novel candidate tumor-suppressor gene for chromosome 13q and may shed new light on strategies that could be used for the diagnosis, prognosis, and treatment of prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.